Corbus Pharma reports Q4 net loss $8.0M; cash $127M after $116M raise; CRB-701 shows 43% ORR

Corbus Pharmaceuticals Holdings, Inc.

Net loss Q4 $8.0M ($1.81/diluted) vs $10.9M ($2.61) YoY; full year loss $44.6M ($10.31).
Cash, equivalents & investments $127M as of Feb 2, 2024 after $116M capital raise; runway 3+ years through Q1 2027.
CRB-701 (Nectin-4 ADC) Ph1 data: 43% ORR, 71% DCR at >=2.7 mg/kg; no DLTs, neuropathy, or skin rash. US Ph1 patient dosing starts March 2024.
FDA cleared IND for CRB-601 (TGFβ blocker); Ph1 start summer 2024. CRB-913 (CB1 inverse agonist) IND filing on track for Q4 2024.
Appointed Dr. Dominic Smethurst as CMO, previously CMO of Bicycle Therapeutics.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Corbus Pharmaceuticals Holdings, Inc. reported the fourth quarter of 2023 and year-ended 2023 results: net income the Company reported a net loss of approximately $8.0 million, or a net loss per diluted share of $1.81, for the three m, EPS a net loss per diluted share of $1.81, for the three months ended December 31, 2023... a net loss per diluted share of $.

Period: the fourth quarter of 2023 and year-ended 2023
Net income: the Company reported a net loss of approximately $8.0 million, or a net loss per diluted share of $1.81, for the three m
EPS: a net loss per diluted share of $1.81, for the three months ended December 31, 2023... a net loss per diluted share of $
Result: reported results

Exact text from the filing

The Company reported a net loss of approximately $8.0 million, or a net loss per diluted share of $1.81, for the three months ended December 31, 2023, compared to a net loss of approximately $10.9 million, or a net loss per diluted share of $2.61, for the same period in 2022. For the year ended December 31, 2023, the Company reported a net loss of approximately $44.6 million, or a net loss per diluted share of $10.31, compared to a net loss of approximately $42.3 million, or a net loss per diluted share of $10.15 for the same period in 2022.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Corbus Pharmaceuticals Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-029667

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.